Andere Sprachen Alnylam Pharmaceuticals, Inc.

Aktien

A0CBCK

US02043Q1076

ALNY

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 08.05.2024			% 5 Tage	% 1. Jan.
152,3 ^USD	-1,32 %		+1,55 %	-20,44 %

07.05.	ALNYLAM PHARMACEUTICALS, INC. : HC Wainwright bleibt bei seiner Kaufempfehlung	ZM
02.05.	Alnylam Pharmaceuticals' Q1 Non-GAAP-Nettoverlust verringert sich bei steigendem Umsatz; Ausblick 2024 bestätigt	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Alnylam Issues 2023 Corporate Responsibility Report	07.05.
Alnylam Pharmaceuticals : 2023 REPORT	07.05.
Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed	02.05.
Alnylam Pharmaceuticals : Q1 2024 GAAP/Non-GAAP Reconciliation ›	02.05.
Earnings Flash (ALNY) ALNYLAM PHARMACEUTICALS Posts Q1 Revenue $494.3M, vs. Street Est of $426.9M	02.05.
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02.05.
Alnylam: Q1 Earnings Snapshot	02.05.
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity	02.05.
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024	02.05.
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia	30.04.
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia	30.04.
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results	18.04.
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	08.04.
Sector Update: Health Care	08.04.
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Chevron, Take-Two, Coinbase, Netflix, American Tower...	08.04.
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension	08.04.
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint	08.04.
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower...	08.04.
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	07.04.
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	07.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alnylam Pharmaceuticals, Inc.

Aktien

A0CBCK

US02043Q1076

ALNY

Andere Sprachen

Filter